Singapore Liver Diseases Therapeutics Market Report 2022 to 2030

Singapore Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, the Singapore Liver Disease Therapeutics market is anticipated to reach a value of $45 Mn from $28 Mn in 2022, growing at a CAGR of 6.3% during 2022-30. Liver Disease Therapeutics in Singapore is dominated by a few domestic pharmaceutical companies such as Gastro-Enterology & Education, Pharmaforte, and AsiaPharm. The Liver Disease Therapeutics market in Singapore is segmented into different types of disease and different therapy types. Some of the major factors affecting the Singapore Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10SGPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Vishwa Modhia

Buy Now

Singapore Liver Disease Therapeutics Analysis Summary

By 2030, the Singapore Liver Disease Therapeutics market is anticipated to reach a value of $45 Mn from $28 Mn in 2022, growing at a CAGR of 6.3% during 2022-30.

Singapore is a high-income, developing island country off the southern tip of the Malay Peninsula in Southeast Asia. GIHep Singapore was founded in 2006 by combining the National Live Endoscopy Workshop and the GESS Annual Scientific Meeting into a single event with the goal of advancing knowledge and practises in gastroenterology and hepatology. It also serves as a hub for multi-centre collaboration in Singapore and around the region.

In Singapore, all nucleos(t)ide analogues, lamivudine, adefovir, tenofovir, telbivudine, and entecavir are approved treatments for CHB. Pegylated interferon alfa 2a is also approved for CHB. These antiviral medications can control CHB but not achieve a functional cure, which is now defined as hepatitis B virus surface antigen loss. According to the latest WHO data published in 2020 Liver Disease Deaths in Singapore reached 209 or 0.88% of total deaths. The age-adjusted Death Rate is 2.40 per 100,000 population ranks Singapore 180^th in the world. Singapore's government spent 6.1% of its GDP on healthcare in 2020.

Singapore Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Chronic liver disease patients may also be eligible for specialised care through the National University Hospital's Liver Transplant Programme, which includes diagnostic tests, specialist consultations, and liver transplant services. Chronic hepatitis B is by far the most common condition, and the National Hepatitis B Childhood Immunization Program, which began in 1987, is the mainstay of this. In terms of liver transplantation, Singapore has four liver transplant centres, two in the commercial sector and two in the public sector. There were 261 liver transplants conducted between 2007 and 2016. These aspects could boost the Singapore Liver Disease Therapeutics market.

Market Restraints

While there are a number of hospitals and medical centres in Singapore that provide liver disease treatment, there are only a few hepatologists and gastroenterologists who have specific training in liver illness. This can lead to longer wait periods for appointments with specialists and may limit access to specialised treatments and therapies. Singapore confronts issues such as skilled labour and housing shortages, as well as an ageing population. It is heavily reliant on exports and imports. These factors may deter new entrants into the Singapore Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Gastro-Enterology & Education Pte Ltd (GEE): GEE is a Singapore-based pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Pharmaforte Singapore Pte Ltd: Pharmaforte Singapore is a pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Dynapharm (Singapore) Pte Ltd: Dynapharm is a Singapore-based pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Silymarin and Ursodeoxycholic acid
AsiaPharm Group Pte Ltd: AsiaPharm Group is a Singapore-based pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin

Recent Notable Updates

April 2022: Gilead Sciences and the National Foundation of Digestive Diseases (NFDD) established a new joint endeavour to improve liver health education in Singapore in honour of World Liver Day. More than $1 Mn in grant funding has been set aside as part of the Gilead Asia Pacific ALL4LIVER Grant programme to support projects to improve viral hepatitis education sponsored by community-based organisations across the Asia Pacific, with a focus on chronic hepatitis B. (HBV). NFDD is the sole Singaporean organisation in the first batch of ALL4LIVER Grant awardees.

Healthcare Policies and Reimbursement Scenarios

In Singapore, the regulation and reimbursement of liver therapeutics are overseen by the Health Sciences Authority (HSA) and the Ministry of Health (MOH), respectively. The HSA is responsible for regulating the safety, efficacy, and quality of liver therapeutics before they can be marketed and used in Singapore. The reimbursement process is managed by the Central Provident Fund (CPF) Board, which determines which therapies are eligible for reimbursement and the conditions under which they will be covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.